EP4725949A1 — Improved solid-phase phosphoramidite-synthesis of long oligonucleotide molecules
Assigned to BioSpring Gesellschaft fur Biotechnologie mbH · Expires 2026-04-15 · 0y expired
What this patent protects
The present invention relates to an improved method of a solid-phase phosphoramidite-synthesis for oligonucleotides, preferably RNA molecules having a length of between 50 and 500 nucleotides, as well as to an improved method of purification of said oligonucleotide molecules.
USPTO Abstract
The present invention relates to an improved method of a solid-phase phosphoramidite-synthesis for oligonucleotides, preferably RNA molecules having a length of between 50 and 500 nucleotides, as well as to an improved method of purification of said oligonucleotide molecules.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.